2023-03-07 10:58:37 ET
- Dyadic International ( NASDAQ: DYAI ) added ~8% in the morning hours Tuesday after announcing that the company has completed dosing for all patients in its Phase 1 trial for COVID-19 booster vaccine candidate DYAI-100.
- DYAI-100, or C1-SARS-CoV-2 RBD vaccine, is a recombinant protein vaccine adjuvanted with Alhydrogel 85 2%.
- The company added that the experimental vaccine was well tolerated, with no reports of serious adverse events to date.
- "The DYAI-100 recombinant protein antigen COVID-19 booster vaccine is an example of our highly efficient and economical approach to the rapid manufacture of large quantities of vaccines," Chief Executive Mark Emalfarb said.
- The trial's initial safety and antibody response results are expected in Q2 2023.
- In October, Dyadic ( DYAI ) announced that South Africa cleared its clinical trial application for DYAI-100, and the company expected to start a Phase 1 trial for the candidate in late 2022.
For further details see:
Dyadic gains after update on early-stage trial for COVID booster shot